Highlight
- Copy number variants (CNVs) have measurable effects on child psychopathology and cognitive development in a large, general-population cohort.
- A duplication at chromosome 14q11.2 is strongly associated with attentional difficulties in late childhood.
- Children carrying CNVs linked to neurodevelopmental disorders exhibit notable impairments in social functioning and cognition, including fluid intelligence and working memory.
- Aggregated CNV risk scores correlate significantly with increased attention problems and multifaceted cognitive deficits, emphasizing cumulative genetic burden.
Study Background
Late childhood represents a pivotal developmental phase marked by critical maturation of cognitive and neurobehavioral domains. Psychiatric disorders often emerge or consolidate during this period, significantly impacting lifelong trajectories. While prior studies highlight the substantial role of common single-nucleotide polymorphisms in inherited psychiatric risk, structural genomic variations such as copy number variants (CNVs) contribute importantly to neurodevelopmental disorder susceptibility. CNVs encompass deletions or duplications of genomic segments and have been well-studied in severe neurodevelopmental conditions; however, their influence on a spectrum of child psychopathology and cognitive profiles in the general population remains inadequately characterized. Addressing this gap, the Adolescent Brain Cognitive Development (ABCD) Study offers a unique opportunity to explore CNV architecture and its association with behavioral and cognitive dimensions in a large, diverse cohort of children.
Study Design
The investigation utilized genotype data from 11,876 children enrolled in the ABCD Study. CNVs were identified using two complementary algorithms to enhance detection accuracy. Rigorous quality control protocols ensured reliable CNV calls, considering factors such as array signal intensity metrics (log R ratio), allelic distributions (B allele frequency), CNV size, concordance between detection algorithms, and the genomic context of variants. Post quality filtering, 8,564 individuals formed the analytic sample, encompassing 5,760 autosomal CNVs across 4,111 carriers.
Phenotypic assessment focused on broad, quantitative psychiatric symptom domains and cognitive performance measures obtained through standardized testing. To evaluate cumulative genetic burden, CNV risk scores were computed incorporating metrics of gene intolerance to inactivation and dosage sensitivity, reflecting the potential functional impact of the variants. Statistical analyses explored associations between specific CNV regions, global CNV burden measures, and dimensional psychiatric and cognitive traits.
Key Findings
The analysis did not identify any CNV regions reaching genome-wide significance after stringent multiple testing correction. Nonetheless, 16 CNV genomic regions showed associations with psychopathology and cognitive phenotypes at an uncorrected significance threshold, underscoring potential loci warranting further validation.
Notably, a duplication at chromosome 14q11.2 emerged as the most robustly associated locus with attentional symptomatology. This finding aligns with emerging literature implicating structural variation in genes relevant to attention regulation.
Children harboring CNVs previously linked with neurodevelopmental disorders demonstrated significantly poorer social functioning and diminished cognitive abilities across several key domains, including fluid intelligence, working memory, and processing speed. These deficits highlight the neurocognitive impact of pathogenic CNVs beyond clinical diagnoses, affecting dimensional traits in the broader population.
Crucially, increased CNV risk scores, capturing aggregated burden of dosage-sensitive and intolerant genes affected by CNVs, were significantly correlated with elevated attention problem scores and widespread cognitive impairments. This comprehensive genetic load effect suggests that cumulative structural variation contributes meaningfully to variability in neurocognitive profiles during development.
Expert Commentary
This study represents one of the largest investigations into CNV effects on child psychopathology and cognition in a general population sample, leveraging rigorous CNV detection and robust phenotypic measurement. The identification of CNV burden correlating with attentional and cognitive domains reinforces the importance of considering rare structural variants in neurodevelopmental research alongside common genetic polymorphisms.
However, despite suggestive associations, the lack of genome-wide significant CNV loci post-correction underlines the complexity and polygenic nature of these traits. Sample size, phenotypic heterogeneity, and the variable penetrance of CNVs likely contribute to this challenge. Future work integrating longitudinal neuroimaging, transcriptomic data, and environmental factors might clarify mechanisms linking CNVs to neurodevelopmental trajectories.
The findings underscore a continuum model of neurodevelopmental variation, where CNVs influence dimensional traits rather than discrete clinical categories alone. Clinically, these insights reinforce the utility of genetic screening for CNVs in children presenting with attentional and cognitive difficulties, particularly when comorbid with social impairments.
Conclusion
The current investigation elucidates the nuanced role of copy number variants in shaping psychopathology and cognitive function in late childhood within a large, representative sample. While individual CNV regions require replication, the aggregate burden of dosage-sensitive CNVs exerts measurable influence on attention and multiple cognitive domains. These results advance our understanding of the genetic architecture underlying complex neurodevelopmental traits and have potential implications for early identification and intervention strategies targeting children at genetic risk. Continued research integrating genetic, neurobiological, and environmental data is essential to fully elucidate the pathways from CNVs to clinical and subclinical neurodevelopmental outcomes.
Funding and ClinicalTrials.gov
The study was supported by funding sources associated with the ABCD Study consortium. The ABCD Study is registered at ClinicalTrials.gov under the identifier NCT02791191.
Reference
Sha Z, Sun KY, Jung B, Barzilay R, Moore TM, Almasy L, Forsyth JK, Prem S, Gandal MJ, Seidlitz J, Glessner JT, Alexander-Bloch AF. Copy Number Variant Architecture of Child Psychopathology and Cognitive Development in the ABCD Study. Am J Psychiatry. 2025 Aug 1;182(8):763-778. doi: 10.1176/appi.ajp.20240445. Epub 2025 Jun 11. PMID: 40495526; PMCID: PMC12318608.
